# Recludix Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/recludix-pharma

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.recludixpharma.com
- Total disclosed funding: $60M
- Latest round: Series A (Nov 15, 2021)
- Investors on record: 3

## About

Recludix Pharma is a biotechnology company focused on developing innovative therapeutics for inflammatory diseases, utilizing biologically-validated targets to create transformative medicines for patients in need.Founded in 2019 in San Diego, US, Recludix Pharma, Inc. specializes in developing therapeutics for inflammatory conditions. The company was co-founded by Brian Hodous and Dan Treiber and is currently led by CEO Nancy Whiting. Recludix successfully raised USD 60.00 mn in SERIES A funding on November 15, 2021, with participation from investors such as Access Industries, New Enterprise Associates, and Westlake Village BioPartners, bringing its total raised to USD 60.00 mn.Recludix Pharma specializes in developing innovative therapeutics aimed at improving the lives of patients suffering from inflammatory diseases. The company focuses on biologically-validated targets, particularly those associated with SH2 domains, which play a critical role in regulating protein activities and mediating intracellular signaling. Through its research and development efforts, Recludix aims to create transformative medicines that address the underlying mechanisms of various inflammatory conditions. The company's products are designed for healthcare providers and ultimately serve patients who require advanced treatments for chronic inflammatory diseases. Recludix operates primarily in the North American and European markets, targeting both established and emerging healthcare systems to maximize patient access to its therapies.Recludix Pharma generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research institutions, focusing on the co-development and commercialization of its therapeutic products. The company engages in B2B transactions, providing access to its proprietary technologies and therapeutic candidates for further development. Revenue structures may involve milestone payments, royalties, and co-marketing agreements, which facilitate a steady influx of capital as products advance through clinical trials and gain regulatory approval. While specific pricing information is not disclosed, Recludix's revenue model leverages its flagship products and services to establish long-term relationships with its clients, ensuring a sustainable business operation centered around innovative healthcare solutions.Recludix Pharma plans to utilize the USD 60.00 mn raised in SERIES A funding to support the development of its therapeutic platform. The company is focused on designing and launching new products aimed at treating inflammatory diseases, though specific release dates are not disclosed. Additionally, Recludix is targeting expansion into emerging markets within North America and Europe to enhance patient access to its therapies.

## Funding rounds

- Series A, Nov 15, 2021, $60M — New Enterprise Associates, Access Industries, Westlake Village BioPartners

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- Access Industries (https://capitalatlas.ai/funds/access-industries) — Series A
- Westlake Village BioPartners (https://capitalatlas.ai/funds/westlake-village-biopartners) — Series A